Page 23 - Delaware Medical Journal - January/February 2021

TREATMENT
REFERENCES
1. Karmen Hanson, A. (2020, March 10). State Medical Marijuana Laws. Retrieved August 12, 2020, from https://www.ncsl.org/ research/health/state-medical-marijuana-laws.aspx
2. Socías ME, Wood E, Lake S, et al. High-intensity cannabis use is associated with retention in opioid agonist treatment: a longitudinal analysis. Addiction. 2018;113(12):2250-2258. doi:10.1111/add.14398
3. Wiese B, Wilson-Poe AR. Emerging evidence for cannabis’ role in opioid use disorder. Cannabis Cannabinoid Res. 2018;3(1):179-189. Published 2018 Sep 1. doi:10.1089/ can.2018.0022
4. Boehnke, K. F., Litinas, E., & Clauw, D. J. (2016). Medical cannabis use is associated with decreased opiate medication use in a retrospective cross-sectional survey of patients with chronic pain. The Journal of Pain, 17(6), 739-744.
5. Abrams DI, Couey P, Shade SB, Kelly ME, Benowitz NL. Cannabinoid-opioid interaction in chronic pain. Clin Pharmacol Ther. 2011;90(6):844-851. doi:10.1038/clpt.2011.188
6. Nunley, K. (2020, April 05). Delaware Marijuana Laws
in 2020. Retrieved August 12, 2020, from https://www. medicalmarijuanainc.com/delaware-marijuana-laws
7. NIDA. 2020, July 8. Delaware: Opioid-Involved Deaths and Related Harms. Retrieved from https://www.drugabuse.gov/ drug-topics/opioids/opioid-summaries-by-state/delaware- opioid-involved-deaths-related-harms on 2020, August 12
8. Karmen Hanson, A. (2020, March 10). State Medical Marijuana Laws. Retrieved August 12, 2020, from https://www.ncsl.org/ research/health/state-medical-marijuana-laws.aspx
9. Centers for Disease Control and Prevention. 2018 Annual Surveillance Report of Drug-Related Risks and Outcomes
— United States. Surveillance Special Report. Centers for Disease Control and Prevention, U.S. Department of Health and Human Services. Published August 31, 2018. Accessed August 12, 2020, from https://www.cdc.gov/ drugoverdose/pdf/ pubs/2018- cdc-drug-surveillance-report.pdf
10. Centers for Disease Control and Prevention. 2019 Annual Surveillance Report of Drug-Related Risks and Outcomes — United States Surveillance Special Report. Centers for Disease Control and Prevention, U.S. Department of Health and Human Services. Published November 1, 2019. Accessed August
12, 2020, from https://www. cdc.gov/drugoverdose/pdf/ pubs/2019-cdc-drug-surveillancereport.pdf.
Sharon Ruth 302.397.0173 Sharon.Ruth@usi.com
www.usi.com/msdis
The Medical Society of Delaware Insurance Services
For over 80 years, the MSDIS consultants in our Wilmington office have responded to the special insurance needs of Delaware’s physicians, surgeons, and other health care professionals.
Working together, now as USI Affinity, the MSDIS consultants remain dedicated to providing you with the insurance solutions and services that you count on to protect you, your family and your practice.
Risk Management Personal Risk Services Property & Casualty Retirement Consulting Employee Benefits
At MSDIS, We’ve Got You Covered.
POWERED BY
©2020 USI Affinity. All right Reserved
Del Med J | January/February 2021 | Vol. 93 | No. 1
23